Intercept and TARGET have recently agreed to extend its strategic partnership revolving around the TARGET-NASH…
Bristol-Myers Squibb extends strategic partnership with TARGET Pharma
Bristol-Myers Squibb has extended its strategic partnership for TARGET-NASH to a new multi-year agreement. Bristol-Myers Squibbis committed to the discovery and development of medicines for fibrosis, including NASH. The study will enroll up to 15,000 patients over the coming years.